Coya Therapeutics reports data from Alzheimer’s Disease therapy trial

Coya Therapeutics has reported data from an academic clinical study of its investigational proprietary biologic, COYA 301, in Alzheimer’s disease (AD) patients.

The open-label, proof-of-concept clinical trial was designed for assessing the tolerability, safety, blood biomarkers, regulatory T cell (Treg) function, and preliminary efficacy of COYA 301 in eight mild-to-moderate AD patients.